VolitionRx Unveils Revolutionary Nu.Q® Vet Feline Test for Cancer Detection
VolitionRx Limited (NYSE AMERICAN: VNRX), a leading multi-national epigenetics company, has announced groundbreaking results from a clinical study showcasing the high accuracy of its Nu.Q® Vet Feline assay. This innovative test is designed to detect lymphoma, the most prevalent type of cancer in cats, with an impressive **100% specificity**—meaning no false positives. The assay has proven capable of detecting over **80%** of feline lymphomas, paving the way for the potential world's first simple, affordable blood-based liquid biopsy test for feline cancer.
Significance of the Nu.Q® Vet Feline Test
The introduction of the Nu.Q® Vet Feline Test addresses a critical need in veterinary medicine. Early cancer diagnosis in cats has historically been challenging, often involving invasive biopsies or costly imaging once symptoms have escalated. Frédéric Wuilque, VP-Global Products at Volition, stated:
“Veterinarians have been asking for a feline solution for years. Our mission is to make cancer screening a routine part of every pet's annual wellness check, and we are pleased to demonstrate that our technology is effective for cats.”
Market Potential and Growth Opportunities
The Nu.Q® Vet Feline Test is positioned to tap into a substantial and rapidly growing market, including:
- Large Population: About **73.8 million** pet cats reside in the United States.
- High Risk: Approximately **1 in 5** cats are expected to develop cancer during their lifetime.
- Senior Segment: Over **25%** of U.S. cats are considered seniors (aged 8+), creating an annual screening opportunity for more than **18 million** pets.
- Market Growth: The North American veterinary oncology market is anticipated to reach **$1.77 billion** by 2025, with a faster growth rate in the feline segment due to heightened owner awareness and focus on feline-specific treatments.
Commercial Opportunities for VolitionRx (VNRX)
Gael Forterre, Chief Commercial Officer at Volition, highlighted the substantial commercial potential of the Nu.Q® Vet Feline Test:
“The publication of this study in a peer-reviewed journal is expected to unlock a **$5 million** contractual milestone payment. We believe that the addition of a feline equivalent could potentially double our total addressable market in the companion animal space.”
About VolitionRx
VolitionRx Limited is a global company dedicated to advancing the field of epigenetics. The company is focused on saving lives and improving outcomes for both people and animals through early disease detection and monitoring. Volition is actively developing cost-effective blood tests for various conditions, including cancers and diseases related to NETosis.
With research and development hubs in Belgium, as well as innovation labs in the U.S. and London, VolitionRx (VNRX) stands at the forefront of veterinary diagnostics.
Contact Information
For media inquiries, please reach out to:
Louise Batchelor, Volition, Louise.Batchelor@volition.com +44 (0)7557 774620
For investor relations, contact:
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568